Introduction to Brivaracetam and current listing status in China

Brivaracetam(Brivaracetam) is an oral or injectable prescription drug used to treat partial-onset (focal) epilepsy in patients one month and older. The drug can be used alone or in combination with other epilepsy drugs to achieve better therapeutic effects. Brivaracetam is thought to reduce the frequency of some seizures by binding to synaptic vesicle protein 2A (SV2A) in the brain.

Epilepsy is a common brain disorder that causes people to have recurring seizures. An epileptic seizure is a manifestation of abnormal brain activity that is usually relatively short-lived. The causes of epilepsy are complex and diverse and may include stroke, infection, tumors, traumatic brain injury, and abnormal brain development. However, in many cases, the specific cause of epilepsy remains unknown. Due to the high incidence of epilepsy and its serious impact on patients' lives, it is particularly important to find effective treatments.

Brivaracetam, as a new generation of anti-epileptic drugs, has been widely used and recognized in the international market. Its latest efficacy and safety have been confirmed in clinical studies. The drug helps balance electrical activity in the brain, effectively controlling the frequency and intensity of epileptic seizures, bringing new treatment hope to epilepsy patients.

However, although brivaracetam has become popular in the international market, the drug is not yet available in China. For patients who are in urgent need of this drug, they can consult some overseas medical service agencies to learn how to obtain and use Brivaracetam. However, it is important to note that the agency must be professionally qualified and reputable. In addition, regarding the issue of generic drugs for Brivaracetam, there is currently no relevant information indicating that generic drugs are available.

In short, as an effective anti-epileptic drug, brivaracetam has demonstrated its unique efficacy and safety in the international market. However, this drug is not yet on the market in China, and patients need to pay attention to relevant channels and drug quality when using it.

References:

https://www.drugs.com/newdrugs/fda-approves-briviact-brivaracetam-partial-onset-seizures-4344.html